---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053963"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:23:36.783647+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Heron Q1 2024 net product sales $34.7M (+17% YoY); net loss per share improves to $(0.02)

## Summary
- Net product sales $34.7M vs $29.6M YoY; net loss per share $(0.02) vs $(0.27).
- Gross margin improved to 76% in Q1 2024 from 43% in Q1 2023.
- ZYNRELEF net sales $5.0M (+43% YoY); FDA expanded indication approved Jan 23, 2024, covering soft tissue and orthopedic procedures.
- Reaffirmed FY2024 guidance: product revenues $138-158M, adjusted operating expenses $108-116M, adjusted EBITDA $(22)-$3M.
- Partnership with CrossLink Life Sciences; 191 CrossLink sales reps trained and engaged with physicians.

## SEC filing metadata
- accession: 0000950170-24-053963
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017024053963/0000950170-24-053963-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017024053963/hrtx-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053963
- JSON: https://secwatch.observer/filing/0000950170-24-053963.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053963.txt

## Key facts
- Earnings Releases
  HERON THERAPEUTICS, INC. /DE/ reported three months ended March 31, 2024 results: revenue Net Product Sales of $34.7 million, EPS Net Loss Per Share $(0.02). Guidance reaffirmed.
  - Period: three months ended March 31, 2024
  - Revenue: Net Product Sales of $34.7 million
  - EPS: Net Loss Per Share $(0.02)
  - Guidance: reaffirmed
  - Result: reported results
  source text: Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017024053963/0000950170-24-053963-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.